N-[4-(4-Chloro-phenyl)-thiazol-2-yl]-2-fluoro-4-trifluoromethyl-benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[4-(4-Chloro-phenyl)-thiazol-2-yl]-2-fluoro-4-trifluoromethyl-benzamide
• 英文别名: N-[4-(4-chlorophenyl)thiazol-2-yl]-2-fluoro-4-trifluoromethylbenzamide；N-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-2-fluoro-4-(trifluoromethyl)benzamide
• 化学式: C₁₇H₉ClF₄N₂OS
• 分子量: 400.784
• InChiKey: JRANGDRPLDRFCR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  70.2
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-氨基-4-(4-氯苯基)噻唑 、 2-氟-4-(三氟甲基)苯甲酰氯 在 吡啶 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.5h， 以47%的产率得到N-[4-(4-Chloro-phenyl)-thiazol-2-yl]-2-fluoro-4-trifluoromethyl-benzamide
  参考文献：
  名称：

  SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE

  摘要：

  这项发明涉及化合物、其药物组合物以及抑制鞘氨醇激酶并治疗或预防过度增殖性疾病、炎症性疾病或血管生成性疾病的方法。

  公开号：

  US20070032531A1

文献信息

• ABCA-1 elevating compounds
  申请人：——

  公开号：US20030220356A1

  公开（公告）日：2003-11-27

  The present invention provides compounds that elevate cellular expression of the ABCA-1 gene, promoting cholesterol efflux from cells and increasing HDL levels in the plasma of a mammal, in particular humans. The compounds are useful for treating coronary artery disease.

  本发明提供了一种能够提高ABCA-1基因细胞表达的化合物，促进胆固醇从细胞中流出并增加哺乳动物（尤其是人类）血浆中的高密度脂蛋白水平。这些化合物可用于治疗冠心病。
• Sphingosine Kinase Inhibitors and Methods of Their Use
  申请人：Smith Charles D.

  公开号：US20100137315A1

  公开（公告）日：2010-06-03

  The invention relates to compounds, pharmaceutical compositions thereof, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

  该发明涉及化合物，其制药组合物以及抑制鞘氨醇激酶和治疗或预防过度增生性疾病，炎症性疾病或血管生成性疾病的方法。
• COMPOUNDS FOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS
  申请人：CV THERAPEUTICS, INC.

  公开号：EP1513534A2

  公开（公告）日：2005-03-16
• Treatment Of Ischemia-Reperfusion Injury
  申请人：Smith Charles D.

  公开号：US20120122870A1

  公开（公告）日：2012-05-17

  Ischemia-reperfusion injury remains a primary cause of morbidity and mortality in individuals who experience disruption of normal blood flow to one or more major organs. For example, there are no clinically proven strategies that prevent acute renal failure following cardiac surgery. The present invention provides a variety of methods for the treatment or prevention of ischemia-reperfusion injury. In one aspect of the invention, a method for treating or preventing ischemia-reperfusion injury includes administering to a subject an effective amount of a sphingosine kinase inhibitor. Sphingosine kinase inhibitors are very effective in the protection against IR-induced acute renal failure and liver failure. Moreover, the effects occur very early after administration, requiring only a very short time of treatment. Toxicology studies with sphingosine kinase inhibitors demonstrate that they have low toxicity, even in long-term treatment.
• US6900219B2
  申请人：——

  公开号：US6900219B2

  公开（公告）日：2005-05-31